Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on May 09, 2019 12:32pm

239 Views

Post# 29729553

RE:37 Million of cheap paper becomes free trading soon

Waterboy45 wrote:
Know the facts.

Please do know the facts. There was no holding period on the shares issued out in February. They are on open market already. There is no imminent dump about to occur.
In fact on a red day like today, ATE is one of the few holding strong.
I'm not even sure why I'm wasting my time responding to this non sense.The only reason is that there will be some people trying to collect info and I hate it when they get fed false information.

Bullboard Posts

Debt-free cannabis company set for next stage of growth